Lorcaserin

Lorcaserin
Clinical data
Trade names	Belviq
Other names	APD-356
AHFS/Drugs.com	Monograph
MedlinePlus	a613014
License data	US DailyMed: Lorcaserin; US FDA: Lorcaserin;
Routes of; administration	Oral
ATC code	A08AA11 (WHO) ;
Legal status
Legal status	US: Schedule IV / Withdrawn;
Pharmacokinetic data
Protein binding	70%
Metabolism	Hepatic (extensive)
Elimination half-life	11 hours
Excretion	Renal (92.3%), Faecal (2.2%)
Identifiers
	IUPAC name (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
CAS Number	616202-92-7 ;
PubChem CID	11658860;
IUPHAR/BPS	2941;
DrugBank	DB04871;
ChemSpider	9833595 ;
UNII	637E494O0Z;
ChEBI	CHEBI:65353;
ChEMBL	ChEMBL360328 ;
CompTox Dashboard (EPA)	DTXSID3048659 ;
ECHA InfoCard	100.237.138
Chemical and physical data
Formula	C11H14ClN
Molar mass	195.69 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1CNCCC2=C1C=C(C=C2)Cl;
	InChI InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1 ; Key:XTTZERNUQAFMOF-QMMMGPOBSA-N ;
	(verify)

Lorcaserin, marketed under the brand name Belviq,^[4]^[5] was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating serotonin receptor the 5-HT_2C receptor in the hypothalamus, a region of the brain which is known to control appetite.^[6] It was approved in 2012, and in 2020, it was removed from the market in the United States due to an increased risk of cancer detected in users of Belviq.^[7]^[1]

^ ^a ^b "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market". U.S. Food and Drug Administration (FDA). 14 January 2020. Retrieved 1 April 2020.
^ ^a ^b ^c ^d Cite error: The named reference DM was invoked but never defined (see the help page).
^ "Lorcaserin Use During Pregnancy". Drugs.com. 4 November 2019. Retrieved 14 January 2020.
^ Cite error: The named reference FDA PR was invoked but never defined (see the help page).
^ "Belviq". Trademarkia. 23 June 2011. Archived from the original on 30 June 2012. Retrieved 27 June 2012.
^ Shukla AP, Kumar RB, Aronne LJ (2015). "Lorcaserin Hcl for the treatment of obesity". Expert Opinion on Pharmacotherapy. 16 (16): 2531–8. doi:10.1517/14656566.2015.1096345. PMID 26472579. S2CID 44520532.
^ "Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug". U.S. Food and Drug Administration (FDA). 13 February 2020. Retrieved 18 February 2020.

[FDA_withdrawal-1] "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market". U.S. Food and Drug Administration (FDA). 14 January 2020. Retrieved 1 April 2020.

[DM-2] Cite error: The named reference DM was invoked but never defined (see the help page).

[Drugs.com_pregnancy-3] "Lorcaserin Use During Pregnancy". Drugs.com. 4 November 2019. Retrieved 14 January 2020.

[FDA_PR-4] Cite error: The named reference FDA PR was invoked but never defined (see the help page).

[trademarkia2-5] "Belviq". Trademarkia. 23 June 2011. Archived from the original on 30 June 2012. Retrieved 27 June 2012.

[6] Shukla AP, Kumar RB, Aronne LJ (2015). "Lorcaserin Hcl for the treatment of obesity". Expert Opinion on Pharmacotherapy. 16 (16): 2531–8. doi:10.1517/14656566.2015.1096345. PMID 26472579. S2CID 44520532.

[7] "Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug". U.S. Food and Drug Administration (FDA). 13 February 2020. Retrieved 18 February 2020.

[1]

[2]

[4]

[5]

[6]

[7]